Philadelphia, PANCT06839456Now EnrollingIRB Ready

Leukemia Clinical Trial in Philadelphia, PA

Access cutting-edge leukemia treatment through this phase 1/2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital of Philadelphia

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related leukemia treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this leukemia clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Leukemia Study in Philadelphia

The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.

Sponsor: Children's Hospital of Philadelphia

Who Can Participate

Inclusion Criteria

Disease for which allogeneic HSCT may be curative.
Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS).
Patients must be 25 years of age and less
Evaluation for organ and infectious status as per our CTTS standard operating procedure.
Signed consent by parent/guardian or able to give consent if 18 years of age and older.
Participants of childbearing potential must have a negative pregnancy test as per institutional SOP.

Exclusion Criteria

Patients who have performance score less than 60.
No suitable donor available for mobilized peripheral stem cells.
Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma.
Planned receipt of alemtuzumab during conditioning.
Patients with an available 10/10 HLA matched sibling donor.
Patients who do not meet institutional disease, organ or infectious criteria. Donor selection and eligibility:
Unrelated donor meets National Marrow Donor Program criteria for donation.
Related donor (at least haploidentical) willing and able to donate mobilized peripheral stem cells.
HLA testing/matching
HLA testing to be done by molecular methods for A, B, C, DRB1, DQB1
Related donor: Must be ≥ 5/10 match
Unrelated donor: 10/10 or 9/10 match
KIR typing for haploidentical donor for hematologic malignancies
Donor specific HLA antibodies (DSA) should be assessed for all subjects receiving an HLA mismatched graft (≤ 9/10).
Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
Donors must be willing to sign consent to participate in this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06839456) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Leukemia Treatment Options in Philadelphia, PA

If you're searching for leukemia treatment options in Philadelphia, PA, this clinical trial (NCT06839456) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Philadelphia, PA

See all leukemia clinical trials recruiting in Philadelphia — not just this study.

Browse Leukemia Trials in Philadelphia →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsChronic Lymphocytic Leukemia TrialsAcute Myeloid Leukemia TrialsMyelodysplastic Syndromes TrialsHeart Attack TrialsPediatric Cancer TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA